TCRX logo

TCRX
Tscan Therapeutics Inc

872
Mkt Cap
$70.58M
Volume
146,733.00
52W High
$2.57
52W Low
$0.8824
PE Ratio
-1.13
TCRX Fundamentals
Price
$1.10
Prev Close
$1.08
Open
$1.08
50D MA
$1.11
Beta
1.37
Avg. Volume
1.33M
EPS (Annual)
-$0.9999
P/B
0.67
Rev/Employee
$72,711.27
$71.51
Loading...
Loading...
News
all
press releases
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits Expectations
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on...
MarketBeat
News Placeholder
More News
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recom...
MarketBeat
News Placeholder
TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday
TScan Therapeutics (NASDAQ:TCRX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3% - Here's What Happened
TScan Therapeutics (NASDAQ:TCRX) Stock Price Up 3% - Here's What Happened...
MarketBeat
News Placeholder
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
PR Newswire
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Hold" from the six brokerages that are currently covering the stock, Marketbeat.com...
MarketBeat
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut TScan Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
HC Wainwright Issues Positive Outlook for TCRX Earnings
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available